Shares of IGM Biosciences (NASDAQ: IGMS) are down 30% in pre-open Monday after the company released clinical data from IGM-2323 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE